Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Clin. Diabetes Healthc.

Sec. Diabetes Multiorgan Complications

Volume 6 - 2025 | doi: 10.3389/fcdhc.2025.1679511

This article is part of the Research TopicDiabetes and Oral HealthView all 6 articles

Periodontitis and GLP-1 Pathways: A New Frontier in Oral-Systemic Health Connections —A Scoping Review

Provisionally accepted
NATALIE  JEONGNATALIE JEONG*Lin-Hsin  ChuangLin-Hsin ChuangYolanda  HoYolanda Ho
  • Department of Periodontology, School of Dental Medicine, Tufts University, Boston, United States

The final, formatted version of the article will be published soon.

Periodontitis, a chronic inflammatory disease of the periodontium, has well-established links to systemic metabolic conditions, particularly diabetes and obesity. Recent research suggests a novel interaction between periodontitis and glucagon-like peptide-1 (GLP-1) pathways, both of which regulate glucose metabolism and inflammation. In this review, we examine the potential bidirectional relationships between periodontitis and GLP-1 signaling and evaluate the therapeutic implications of GLP-1 receptor agonists (GLP-1 RAs) in periodontal disease. A systematic search of PubMed, Embase, and the Cochrane Library identified 52 studies published between 1990 and 2025, ranging from in vitro and animal studies to human clinical and observational research. Findings indicate a multifaceted relationship between GLP-1 pathways and periodontal disease. Periodontitis may impair GLP-1 signaling and exacerbate glucotoxicity and lipotoxicity in individuals with diabetes or obesity. Several periodontopathic bacteria, notably Porphyromonas gingivalis, produce DPP-4-like enzymes that degrade GLP-1 and potentially disrupt glucose regulation. GLP-1 RAs, such as liraglutide and exendin-4, demonstrated anti-inflammatory, osteoprotective, and regenerative effects in preclinical models. Additionally, studies identified host and microbial DPP-4 activity as key mechanistic links between periodontal inflammation and systemic insulin resistance. This review highlights a novel and clinically relevant intersection between periodontitis and GLP-1 biology. GLP-1 RAs and DPP-4 inhibitors may offer dual benefits for metabolic control and periodontal health. Further research is needed to define delivery strategies, assess efficacy across patient populations, and explore the therapeutic targeting of DPP-4 activity in both host and microbial contexts.

Keywords: GLP-1, Periodontitis, oral-systemic association, Diabetes Mellitus, Obesity

Received: 04 Aug 2025; Accepted: 13 Oct 2025.

Copyright: © 2025 JEONG, Chuang and Ho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: NATALIE JEONG, natalie.jeong@tufts.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.